Typical starting doses include: Semaglutide (Wegovy): 0.25 mg weekly Tirzepatide (Zepbound): 2.5 mg weekly These starting doses were studied in programs such as the STEP and SURMOUNT trials and were gradually increased to achieve validated metabolic outcomes
Real-world studies such as SURMOUNT-REAL, a five-year real-world observational program, are designed to answer questions that randomised trials cannot
Balasa R, Barcutean L, Mosora O, Manu D
Medicines and surgery Overweight and obesity management (NG246 chapter)
[DOI] [PubMed] [Google Scholar] 57.Finan B., Yang B., Ottaway N., Stemmer K., Mller T.D., Yi C.X., Habegger K., Schriever S.C., Garca-Cceres C., Kabra D.G., et al
doi: 10.1016/j.plipres.2019.101020 43 SchwarzlerJMayrLRadlingerBGrabherrFPhilippMTexlerBet al